title: Common toxicities of mammalian target of rapamycin inhibitors.
abstract: The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.
authors.affiliation: Cancer Therapy & Research Center at The University of Texas Health Science Center San Antonio, TX 78249, USA.
authors.forename: Scott A
authors.initials: SA
authors.lastname: Soefje
authors.forename: Anand
authors.initials: A
authors.lastname: Karnad
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Brenner
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D000068338:Everolimus; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus